denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Biological therapies, Clinical Practice (Health Services and Quality), Workforce, Diversity, Equity, and Inclusion (DEI) , Hemoglobinopathies, Diseases, Gene Therapy, Therapies
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Biological therapies, Clinical Practice (Health Services and Quality), Workforce, Diversity, Equity, and Inclusion (DEI) , Hemoglobinopathies, Diseases, Gene Therapy, Therapies
Saturday, December 9, 2023: 9:30 AM-11:00 AM
Hall A
(San Diego Convention Center)
Lecture Title:
Looking for Money in All the “Right” Places for Sickle Cell
Co-chairs:
Payal Desai, MD, Atrium Health
and
Julie Kanter, MD, University of Alabama At Birmingham
Disclosures:
Desai: University of Pittsburgh: Research Funding; University of Tennessee: Research Funding; POC Detection of Hemoglobin Sickling via Magnetic Fractionation: Patents & Royalties: (Pending); US Food & Drug Administration: Research Funding; NIH: Research Funding; Novartis: Research Funding, Speakers Bureau; Chiesi: Consultancy; PCORI: Research Funding; Vertex: Consultancy; Forma Therapeutics: Consultancy. Kanter: Chiesi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Austin Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bausch: Honoraria; Watkins, Lourie, Roll&Chance: Consultancy; Guidepoint Global: Consultancy; Fulcrum: Consultancy; ECOR1: Consultancy; Beam: Consultancy, Honoraria; OptumRx: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird Bio: Consultancy; GLG: Consultancy; Cowen: Consultancy.
As care for people with sickle cell disease gets more complex and there are more treatment options available, it is imperative that all people with SCD receive care through a sickle cell center.
Over the last several years, ASH has developed a workshop and blueprint for the creation of Sickle Cell Disease Centers. Despite their necessity, it can still be difficult to ensure funding for these centers. This session will focus on alternative ways to supplement funding for sickle cell disease centers.
See more of: Special-Interest Sessions